Novartis Moving COPD Antagonist Into Phase III Trials, Triggering Milestones For Sosei
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Novartis' muscarinic antagonist NVA237 for treating chronic obstructive pulmonary disease is slated to enter Phase III clinical trials in the United States and the European Union in the second half of this year, according to a joint announcement by Japanese biopharmaceutical start-up Sosei Group and the U.K.'s Vectura Group
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)